• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Monday 12/17/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Neural Injury

  • 1:52 PM

    ROCKVILLE, Md., Dec. 16, 2016, RGRX, /PRNewswire/ — RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received notice of Intent to Grant a patent from the European Patent Office for treating neural injury using Thymosin beta 4 (Tβ4), the active pharmaceutical ingredient in the RegeneRx’s proprietary drug candidate, RGN-352. The treatment claims include treating neural injury by remyelinating damaged neurons using Tβ4,

    Read more
Public Wire Banner